The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback